7th International Immunoglobulin Conference: Poster Presentations
Summary The pan‐European survey provides useful information on the accessibility and trends of intravenous and subcutaneous immunoglobulin (IVIg/SCIg) therapy, which is used to treat primary immunodeficiency disorders (PIDs). Although immunoglobulin (Ig) therapy is the first‐line treatment for PIDs,...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental immunology 2014-12, Vol.178 (S1), p.162-162 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 162 |
|---|---|
| container_issue | S1 |
| container_start_page | 162 |
| container_title | Clinical and experimental immunology |
| container_volume | 178 |
| creator | Warnatz, K. Ballow, M. Stangel, M. Bril, V. |
| description | Summary
The pan‐European survey provides useful information on the accessibility and trends of intravenous and subcutaneous immunoglobulin (IVIg/SCIg) therapy, which is used to treat primary immunodeficiency disorders (PIDs). Although immunoglobulin (Ig) therapy is the first‐line treatment for PIDs, the mechanisms of action of Ig therapy may differ according to the condition it is used to treat. Moreover, intriguing presentations suggest that further investigation is required to understand more clearly both the haematological and immunoregulatory effects of therapeutic immunoglobulin. This can ultimately provide more information on optimizing Ig therapy efficacy, and establish whether individualized dosing regimens for patients will be conducive to better clinical outcomes. In addition to treating autoimmune and inflammatory conditions, there is evidence to suggest that immunoglobulins can potentially play a role in transplantation, which warrants further investigation for future use. |
| doi_str_mv | 10.1111/cei.12554 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4285534</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1641203189</sourcerecordid><originalsourceid>FETCH-LOGICAL-p2644-cf2b259fbc4ed1b6e88821fa0ed20f4f97e7af7d343c78ac5fe05f9f5602a2923</originalsourceid><addsrcrecordid>eNpdkV9LwzAUxYMoOqcPfgEp-OJLtyRN0tYHYQz_FAT3oM8hbW-2SprMplX89mabipqX5HJ_ORzOQeiM4AkJZ1pBMyGUc7aHRiQRPKaU5ftohDHO45xgdoSOvX8JoxCCHqKjDSsyzEdolvarqLA9dFb1jbPKREXbDtYtjSsH09ho7qyGDmwFV9HC-UBGiw482H77wZ-gA62Mh9Ove4yeb2-e5vfxw-NdMZ89xGsqGIsrTUvKc11WDGpSCsiyjBKtMNQUa6bzFFKl0zphSZVmquIaMNe55gJTRXOajNH1Tnc9lC3UVTDQKSPXXdOq7kM61ci_G9us5NK9SUYzzoPsGF1-CXTudQDfy7bxFRijLLjBSyIYoTghWR7Qi3_oixtCQmZLbVLk6cbR-W9HP1a-0w3AdAe8NwY-fvYEy01tMtQmt7XJ-U2xfSSfCUCKxQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1640666572</pqid></control><display><type>article</type><title>7th International Immunoglobulin Conference: Poster Presentations</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Oxford Journals</source><creator>Warnatz, K. ; Ballow, M. ; Stangel, M. ; Bril, V.</creator><creatorcontrib>Warnatz, K. ; Ballow, M. ; Stangel, M. ; Bril, V.</creatorcontrib><description>Summary
The pan‐European survey provides useful information on the accessibility and trends of intravenous and subcutaneous immunoglobulin (IVIg/SCIg) therapy, which is used to treat primary immunodeficiency disorders (PIDs). Although immunoglobulin (Ig) therapy is the first‐line treatment for PIDs, the mechanisms of action of Ig therapy may differ according to the condition it is used to treat. Moreover, intriguing presentations suggest that further investigation is required to understand more clearly both the haematological and immunoregulatory effects of therapeutic immunoglobulin. This can ultimately provide more information on optimizing Ig therapy efficacy, and establish whether individualized dosing regimens for patients will be conducive to better clinical outcomes. In addition to treating autoimmune and inflammatory conditions, there is evidence to suggest that immunoglobulins can potentially play a role in transplantation, which warrants further investigation for future use.</description><identifier>ISSN: 0009-9104</identifier><identifier>EISSN: 1365-2249</identifier><identifier>DOI: 10.1111/cei.12554</identifier><identifier>PMID: 25546805</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Clinical outcomes ; Humans ; Immunization, Passive - methods ; Immunoglobulins ; Immunoglobulins - immunology ; Immunoglobulins - therapeutic use ; Immunoglobulins, Intravenous - immunology ; Immunoglobulins, Intravenous - therapeutic use ; Immunologic Deficiency Syndromes - immunology ; Immunologic Deficiency Syndromes - therapy ; Infusions, Subcutaneous - methods ; Poster Presentations</subject><ispartof>Clinical and experimental immunology, 2014-12, Vol.178 (S1), p.162-162</ispartof><rights>2014 British Society for Immunology</rights><rights>2014 British Society for Immunology.</rights><rights>Copyright © 2014 British Society for Immunology</rights><rights>Copyright © 2014 British Society for Immunology 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285534/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285534/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,729,782,786,887,27931,27932,53798,53800</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25546805$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Warnatz, K.</creatorcontrib><creatorcontrib>Ballow, M.</creatorcontrib><creatorcontrib>Stangel, M.</creatorcontrib><creatorcontrib>Bril, V.</creatorcontrib><title>7th International Immunoglobulin Conference: Poster Presentations</title><title>Clinical and experimental immunology</title><addtitle>Clin Exp Immunol</addtitle><description>Summary
The pan‐European survey provides useful information on the accessibility and trends of intravenous and subcutaneous immunoglobulin (IVIg/SCIg) therapy, which is used to treat primary immunodeficiency disorders (PIDs). Although immunoglobulin (Ig) therapy is the first‐line treatment for PIDs, the mechanisms of action of Ig therapy may differ according to the condition it is used to treat. Moreover, intriguing presentations suggest that further investigation is required to understand more clearly both the haematological and immunoregulatory effects of therapeutic immunoglobulin. This can ultimately provide more information on optimizing Ig therapy efficacy, and establish whether individualized dosing regimens for patients will be conducive to better clinical outcomes. In addition to treating autoimmune and inflammatory conditions, there is evidence to suggest that immunoglobulins can potentially play a role in transplantation, which warrants further investigation for future use.</description><subject>Clinical outcomes</subject><subject>Humans</subject><subject>Immunization, Passive - methods</subject><subject>Immunoglobulins</subject><subject>Immunoglobulins - immunology</subject><subject>Immunoglobulins - therapeutic use</subject><subject>Immunoglobulins, Intravenous - immunology</subject><subject>Immunoglobulins, Intravenous - therapeutic use</subject><subject>Immunologic Deficiency Syndromes - immunology</subject><subject>Immunologic Deficiency Syndromes - therapy</subject><subject>Infusions, Subcutaneous - methods</subject><subject>Poster Presentations</subject><issn>0009-9104</issn><issn>1365-2249</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkV9LwzAUxYMoOqcPfgEp-OJLtyRN0tYHYQz_FAT3oM8hbW-2SprMplX89mabipqX5HJ_ORzOQeiM4AkJZ1pBMyGUc7aHRiQRPKaU5ftohDHO45xgdoSOvX8JoxCCHqKjDSsyzEdolvarqLA9dFb1jbPKREXbDtYtjSsH09ho7qyGDmwFV9HC-UBGiw482H77wZ-gA62Mh9Ove4yeb2-e5vfxw-NdMZ89xGsqGIsrTUvKc11WDGpSCsiyjBKtMNQUa6bzFFKl0zphSZVmquIaMNe55gJTRXOajNH1Tnc9lC3UVTDQKSPXXdOq7kM61ci_G9us5NK9SUYzzoPsGF1-CXTudQDfy7bxFRijLLjBSyIYoTghWR7Qi3_oixtCQmZLbVLk6cbR-W9HP1a-0w3AdAe8NwY-fvYEy01tMtQmt7XJ-U2xfSSfCUCKxQ</recordid><startdate>201412</startdate><enddate>201412</enddate><creator>Warnatz, K.</creator><creator>Ballow, M.</creator><creator>Stangel, M.</creator><creator>Bril, V.</creator><general>Oxford University Press</general><general>BlackWell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201412</creationdate><title>7th International Immunoglobulin Conference: Poster Presentations</title><author>Warnatz, K. ; Ballow, M. ; Stangel, M. ; Bril, V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p2644-cf2b259fbc4ed1b6e88821fa0ed20f4f97e7af7d343c78ac5fe05f9f5602a2923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Clinical outcomes</topic><topic>Humans</topic><topic>Immunization, Passive - methods</topic><topic>Immunoglobulins</topic><topic>Immunoglobulins - immunology</topic><topic>Immunoglobulins - therapeutic use</topic><topic>Immunoglobulins, Intravenous - immunology</topic><topic>Immunoglobulins, Intravenous - therapeutic use</topic><topic>Immunologic Deficiency Syndromes - immunology</topic><topic>Immunologic Deficiency Syndromes - therapy</topic><topic>Infusions, Subcutaneous - methods</topic><topic>Poster Presentations</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Warnatz, K.</creatorcontrib><creatorcontrib>Ballow, M.</creatorcontrib><creatorcontrib>Stangel, M.</creatorcontrib><creatorcontrib>Bril, V.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical and experimental immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Warnatz, K.</au><au>Ballow, M.</au><au>Stangel, M.</au><au>Bril, V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>7th International Immunoglobulin Conference: Poster Presentations</atitle><jtitle>Clinical and experimental immunology</jtitle><addtitle>Clin Exp Immunol</addtitle><date>2014-12</date><risdate>2014</risdate><volume>178</volume><issue>S1</issue><spage>162</spage><epage>162</epage><pages>162-162</pages><issn>0009-9104</issn><eissn>1365-2249</eissn><abstract>Summary
The pan‐European survey provides useful information on the accessibility and trends of intravenous and subcutaneous immunoglobulin (IVIg/SCIg) therapy, which is used to treat primary immunodeficiency disorders (PIDs). Although immunoglobulin (Ig) therapy is the first‐line treatment for PIDs, the mechanisms of action of Ig therapy may differ according to the condition it is used to treat. Moreover, intriguing presentations suggest that further investigation is required to understand more clearly both the haematological and immunoregulatory effects of therapeutic immunoglobulin. This can ultimately provide more information on optimizing Ig therapy efficacy, and establish whether individualized dosing regimens for patients will be conducive to better clinical outcomes. In addition to treating autoimmune and inflammatory conditions, there is evidence to suggest that immunoglobulins can potentially play a role in transplantation, which warrants further investigation for future use.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>25546805</pmid><doi>10.1111/cei.12554</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9104 |
| ispartof | Clinical and experimental immunology, 2014-12, Vol.178 (S1), p.162-162 |
| issn | 0009-9104 1365-2249 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4285534 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection; Oxford Journals |
| subjects | Clinical outcomes Humans Immunization, Passive - methods Immunoglobulins Immunoglobulins - immunology Immunoglobulins - therapeutic use Immunoglobulins, Intravenous - immunology Immunoglobulins, Intravenous - therapeutic use Immunologic Deficiency Syndromes - immunology Immunologic Deficiency Syndromes - therapy Infusions, Subcutaneous - methods Poster Presentations |
| title | 7th International Immunoglobulin Conference: Poster Presentations |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T23%3A00%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=7th%20International%20Immunoglobulin%20Conference:%20Poster%20Presentations&rft.jtitle=Clinical%20and%20experimental%20immunology&rft.au=Warnatz,%20K.&rft.date=2014-12&rft.volume=178&rft.issue=S1&rft.spage=162&rft.epage=162&rft.pages=162-162&rft.issn=0009-9104&rft.eissn=1365-2249&rft_id=info:doi/10.1111/cei.12554&rft_dat=%3Cproquest_pubme%3E1641203189%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1640666572&rft_id=info:pmid/25546805&rfr_iscdi=true |